Please login to the form below

Not currently logged in
Email:
Password:

SkyePharma

This page shows the latest SkyePharma news and features for those working in and with pharma, biotech and healthcare.

Consilium Strategic Communications wins Vectura account

Consilium Strategic Communications wins Vectura account

Consilium Strategic Communications wins Vectura account. Will advise on financial and corporate PR following SkyePharma merger. ... Consilium Strategic Communications has been selected by Vectura to advise on its international financial and corporate PR

Latest news

  • Vectura's Flutiform flunks phase III COPD test Vectura's Flutiform flunks phase III COPD test

    The product was originally developed by SkyePharma, which merged with Vectura earlier this year.

  • Vectura to merge with SkyePharma in £441m deal Vectura to merge with SkyePharma in £441m deal

    Vectura to merge with SkyePharma in £441m deal. Will form a “ one-stop shop” for specialist respiratory medicine development. ... UK-listed Vectura and SkyePharma have agreed to merge their operations into a single specialist respiratory medicine

  • Successful partnerships in pharma: Skyepharma and Mundipharma Successful partnerships in pharma: Skyepharma and Mundipharma

    Successful partnerships in pharma: Skyepharma and Mundipharma. Why skills and flexibility matter more than sheer size. ... Grant (pictured left) is CEO at Skyepharma and Toufar is chief marketing officer at Mundipharma International.

  • Double asthma approval in Japan lifts SkyePharma Double asthma approval in Japan lifts SkyePharma

    Double asthma approval in Japan lifts SkyePharma. Regulatory wins for company’ s commercial partners GSK and Kyorin. ... SkyePharma is celebrating after its commercial partners scored regulatory approvals in Japan for two asthma drugs.

  • COPD-asthma market to reach $47bn in 2017

    These medicines include SkyePharma's Flutiform (fluticasone/formoterol) to treat asthma, Novartis' Arcapta Neohaler for patients with COPD, and GSK's own Seretide follow-up Relvar (formerly Relovair) for both asthma

More from news
Approximately 4 fully matching, plus 57 partially matching documents found.

Latest Intelligence

  • Deal Watch March 2016 Deal Watch March 2016

    Licence. $855. SkyePharma/ Vectura. Respiratory Drugs. Merger. $627. Padlock Therapeutics/ BMS.

  • A new route to market A new route to market

    My most recent assignment was at Skyepharma in Switzerland, although I have worked with both biotech and pharma companies of varying sizes, on technology transfer and licensing agreements at all stages

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Synergy Vision

Synergy Vision believe in delivering medical communications that make a difference to healthcare professionals and patients. Our synergy of pharma...

Latest intelligence

Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....
The rise of vertical integration in the US payer landscape
Is it a solution to addressing the challenges of the value-based marketplace?...
Light_bulb_Stock_Market.jpg
Creativity has lost its worth
Creativity has lost its worth, and sadly it is undermining effectiveness...

Infographics